Core Insights - CSL plans to invest $1.5 billion over the next five years in the US to expand its plasma therapy production, aiming to create hundreds of high-quality American jobs [1] - The investment is intended to strengthen CSL's plasma-derived therapies manufacturing and secure its supply chain in the US, reflecting the growing clinical need for immunoglobulin [2] - CSL Behring, the plasma therapies unit, generated $11.16 billion in revenue in 2024, with a 7% growth in its immunoglobulin portfolio compared to 2023 [2][3] Company Strategy - CSL's CEO emphasized the importance of US production capacity for plasma-derived therapies, which are crucial for treating rare or serious diseases, and highlighted the company's commitment to patient care and innovation [4] - Since 2018, CSL has invested over $3 billion in US operations, creating more than 6,500 jobs and increasing its US workforce to nearly 19,000, representing about 65% of its total workforce [4] Industry Context - The pharmaceutical industry is experiencing a trend of onshoring manufacturing in the US, driven by tariff threats and the need to avoid levies on pharmaceutical products [5] - Other major pharmaceutical companies are also making significant investments in the US, with Roche planning $50 billion, GSK pledging $30 billion, and Johnson & Johnson set to invest $55 billion [5][6]